since initial FDA approval in AD2,a

Globally, ≈750,000 patients
treated
with DUPIXENT
worldwide across 5
indications1,b,c

a FDA approved since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and
2022 for infants to preschoolers (aged 6 months to 5 years) with uncontrolled moderate-to-severe atopic dermatitis.2

b The worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China,
France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this
worldwide patient number. Data through August 2023.

c ≈387,000 US AD patients have filled at least 1 DUPIXENT prescription based on IQVIA National Source of Business (NSOB)
data as of June 2023.

REAL PATIENT STORIES

Review real stories of patients who were appropriate for DUPIXENT.